Weight Regain Observed in Patients After Ending Obesity Drug Treatment
HIDALGO COUNTY, TEXAS, JUL 22 – A meta-analysis of 11 trials found patients typically begin regaining weight about eight weeks after stopping anti-obesity medications, with regain continuing for 20 weeks before stabilizing.
- On Tuesday, the BMC Medicine review showed that data from 11 clinical trials involving nearly 2,500 participants found patients broadly regained weight starting eight weeks after stopping anti-obesity medications, impacting long-term treatment strategies.
- Reviewing prior findings, researchers led by Xiaoling Cai examined long-term AOM effects and identified a significant research gap, prompting a meta-analysis to address this issue.
- Their analysis showed weight regain began eight weeks after AOM discontinuation, indicating a pattern, the study found, lasting about 20 weeks before plateauing.
- The review recommends more long-term studies with extended follow-up to better understand weight regain patterns after anti-obesity medication discontinuation.
- Considering medication differences, the study suggests these patterns could guide personalized long-term obesity management strategies, emphasizing the need to tailor treatments based on medication type and lifestyle consistency.
40 Articles
40 Articles
We need to talk about the dark side of the Ozempic boom: A new eating disorder crisis
Chevese Turner is 20 years into recovery from binge-eating disorder. And yet, she was prescribed Mounjaro, a diabetes drug that triggers dramatic weight loss.Alyssa Schukar for BIThe last thing Chevese Turner needed was medication to help her lose weight. Twenty years into recovery from binge eating disorder and atypical anorexia, she was done trying to whittle her physique into something it didn't want to be.But after developing diabetes a few …
Medicines like Ozempic promise help with weight loss. And studies show that this really works. However, there is a catch.
Dr Reddy’s Joins Generic Drugmakers Readying Semaglutide Launch
India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy — next year, joining companies including Biocon Ltd. and Sandoz Group AG.
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium